Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN9533 in healthy adults
NCT06665828Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thromboembolic disease comparing REGN9533 Arm with Placebo Arm (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 100 days and Severity of Treatment Emergent Adverse Events at 100 days. Started Mar 2025; status: completed.
02
Drugs
REGN9533
03
Conditions
thromboembolic disease
Beyond the preview
Go deeper on NCT06665828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665828.